GLP-1 treatment linked to lower risk of hospitalization and death in older adults with fatty liver disease

A caller Houston Methodist Research Institute survey finds that older adults with metabolic dysfunction-associated steatotic liver illness (MASLD) who received GLP-1-based attraction experienced importantly little risks of liver disease–related complications, hospitalization and decease compared with akin patients who did not person the treatment.